St. Michael's FinancialJul 15, 2025

🔬 Biotech may have stumbled in FY25—but opportunity is building for FY26.

HB Biotechnology posted 23% outperformance in one of the toughest years for the sector. At St. Michaels Financial Services, we explore why strong fundamentals, thoughtful diversification, and regulatory shifts could drive a biotech rebound.

https://medium.com/@st.michaels.financial.serivces/biotechs-underrated-upside-positioning-for-opportunity-in-fy26-120e7ed2b432

#Biotech #Investing #FinancialStrategy #Markets #WealthManagement #StMichaelsFinancial #HealthcareEquities

Biotech’s Underrated Upside: Positioning for Opportunity in FY26

FY25 was no easy ride for healthcare and biotech investors. While global equity markets, including the ASX200, soared to record highs in early 2025, the biotech sector posted some of its weakest…

Medium